Pharmacology of cannabinoid CB1 and CB2 receptors

Pharmacology and Therapeutics

Volumn 74, Issue 2, 1997, Pages 129-180

  Pertwee, Roger G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Anandamide; Cannabinoid receptor agonists and antagonists; Cannabinoid receptor effector systems; Cannabinoid receptors; Endogenous cannabinoids; SR141716A

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 6 BROMOPRAVADOLINE; 6 IODOPRAVADOLINE; CANNABINOID; CANNABINOID B1 RECEPTOR; CANNABINOID B2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DEXANABINOL; DRONABINOL; FOSFAZINOMYCIN; HU 243; ION CHANNEL; RECEPTOR SUBTYPE; RIMONABANT; SR 54461; TRITIUM; UNCLASSIFIED DRUG; WIN 56098; CALCIUM; CYCLIC AMP; CYCLOHEXANOL DERIVATIVE; DRUG RECEPTOR;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; BINDING AFFINITY; BINDING SITE; BIOASSAY; CENTRAL NERVOUS SYSTEM; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; LIGAND BINDING; MALE; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BINDING COMPETITION; BRAIN; CELL CULTURE; CELL MEMBRANE; CLASSIFICATION; DRUG EFFECT; LEUKOCYTE; METABOLISM; PHYSIOLOGY; SPLEEN; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; BRAIN; CALCIUM; CANNABINOIDS; CELL MEMBRANE; CELLS, CULTURED; CYCLIC AMP; CYCLOHEXANOLS; HUMANS; LEUKOCYTES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SIGNAL TRANSDUCTION; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030611978     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(97)82001-3     Document Type: Article

References (207)

1. Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37:1994;1889-1893.
2. 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol. Biochem. Behav. 46:1993;575-579.
3. Adams I.B., Ryan W., Singer M., Thomas B.F., Compton D.R., Razdan R.K., Martin B.R. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J. Pharmacol. Exp. Ther. 273:1995;1172-1181.
4. 9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci. Biobehav. Revs. 16:1992;55-62.
5. Barg J., Fride E., Hanuš L., Levy R., Matus-Leibovitch N., Heldman E., Bayewitch M., Mechoulam R., Vogel Z. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur. J. Pharmacol. 287:1995;145-152.
6. 9-tetrahydrocannabinol discrimination in rats. Psychopharmacology. 118:1995;419-424.
7. Bayewitch M., Avidor-Reiss T., Levy R., Barg J., Mechoulam R., Vogel Z. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett. 375:1995;143147.
8. 9-Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J. Biol. Chem. 271:1996;9902-9905.
9. Beal J.E., Olson R., Laubenstein L., Morales J.O., Bellman P., Yangco B., Lefkowitz L., Plasse T.F., Shepard K.V. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Sympt. Manag. 10:1995;89-97.
10. Belue R.C., Howlett A.C., Westlake T.M., Hutchings D.E. The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxicol. Teratol. 17:1995;25-30.
11. Bidaut-Russell M., Howlett A.C. Cannabinoid receptor-regulated cyclic AMP accumulation in the rat striatum. J. Neurochem. 57:1991;1769-1773.
12. Bidaut-Russell M., Devane W.A., Howlett A.C. Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. J. Neurochem. 55:1990;21-26.
13. Bouaboula M., Rinaldi M., Carayon P., Carillon C., Delpech B., Shire D., Le Fur G., Casellas P. Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem. 214:1993;173-180.
14. 1 induces krox-24 expression in human astrocytoma cells. J. Biol. Chem. 270:1995a;13973-13980.
15. Bouaboula M., Poinot-Chazel C., Bourrié B., Canat X., Calandra B., Rinaldi-Carmona M., Le Fur G., Casellas P. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 312:1995b;637-641.
16. 2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem. 237:1996;704-711.
17. 1 receptor: determination of helix ends and helix orientation. Life Sci. 56:1995;1971-1982.
18. Caenazzo L., Hoehe M.R., Hsieh W.-T., Berrettini W.H., Bonner T.I., Gershon E.S. HindIII identifies a two allele DNA polymorphism of the human cannabinoid receptor gene (CNR). Nucl. Acids Res. 19:1991;4798.
19. Casiano F.M., Arnold R., Haycock D., Kuster J., Ward S.J. Putative aminoalkylindoles (AAI) antagonists. NIDA Res. Monogr. 105:1990;295-296.
20. Caulfield M.P., Brown D.A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br. J. Pharmacol. 106:1992;231-232.
21. Chakrabarti A., Onaivi E.S., Chaudhuri G. Cloning and sequencing of a cDNA encoding the mouse brain-type cannabinoid receptor protein. DNA Seq.-J. Seq. Map. 5:1995;385-388.
22. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
23. Childers S.R., Sexton T., Roy M.B. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem. Pharmacol. 47:1994;711-715.
24. Compton D.R., Rice K.C., de Costa B.R., Razdan R.K., Melvin L.S., Johnson M.R., Martin B.R. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther. 265:1993;218-226.
25. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277:1996;586-594.
26. Condie R., Herring A., Koh W.S., Lee M., Kaminski N.E. Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. J. Biol. Chem. 271:1996;13175-13183.
27. Coutts A.A., Pertwee R.G. Effect of cannabinoid agonists and SR141716A on acetylcholine release from the myenteric plexus of the guinea-pig small intestine. Br. J. Pharmacol. 119:1996;312P. (Proc. Suppl.).
28. 1 cannabinoid receptors and possibly also a cannabinoid receptor ligand. Br. J. Pharmacol. 116:1995;46P. (Proc. Suppl.).
29. Daaka Y., Friedman H., Klein T.W. Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation. J. Pharmacol. Exp. Ther. 276:1996;776-783.
30. Das S.K., Paria B.C., Chakraborty I., Dey S.K. Cannabinoid ligand-receptor signaling in the mouse uterus. Proc. Natl. Acad. Sci. USA. 92:1995;4332-4336.
31. Deadwyler S.A., Hampson R.E., Bennett B.A., Edwards T.A., Mu J., Pacheco M.A., Ward S.J., Childers S.R. Cannabinoids modulate potassium current in cultured hippocampal neurons. Recept. Channels. 1:1993;121-134.
32. Deadwyler S.A., Hampson R.E., Childers S.R. Functional significance of cannabinoid receptors in brain. Pertwee R.G. Cannabinoid Receptors. 1995a;205-231 Academic Press, London.
33. Deadwyler S.A., Hampson R.E., Mu J., Whyte A., Childers S. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J. Pharmacol. Exp. Ther. 273:1995b;734-743.
34. Deutsch D.G., Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46:1993;791-796.
35. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
36. Devane W.A., Breuer A., Sheskin T., Järbe T.U.C., Eisen M.S., Mechoulam R. A novel probe for the cannabinoid receptor. J. Med. Chem. 35:1992a;2065-2069.
37. Devane W.A., Hanuš L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992b;1946-1949.
38. Dewey W.L. Cannabinoid pharmacology. Pharmacol. Revs. 38:1986;151-178.
39. Diaz S., Specter S., Coffey R.G. Suppression of lymphocyte adenosine 3′:5′-cyclic monophosphate (cAMP) by delta-9-tetrahydrocannabinol. Int. J. Immunopharmacol. 15:1993;523-532.
40. Di Marzo V. Arachidonic acid and eicosanoids as targets and effectors in second messenger interactions. Prostaglandins Leukot. Essent. Fatty Acids. 53:1995;239-254.
41. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.-C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
42. 18 neuroblastoma cells. Biochem. J. 316:1996;977-984.
43. Dove Pettit D.A., Showalter V.M., Abood M.E., Cabral G.A. Expression of a cannabinoid receptor in baculovirus-infected insect cells. Biochem. Pharmacol. 48:1994;1231-1243.
44. Dutta A.K., Sard H., Ryan W., Razdan R.K., Compton D.R., Martin B.R. The synthesis and pharmacological evaluation of the cannabinoid antagonist SR141716A. Med. Chem. Res. 5:1995;54-62.
45. Eissenstat M.A., Bell M.R., D'Ambra T.E., Alexander E.J., Daum S.J., Ackerman J.H., Gruett M.D., Kumar V., Estep K.G., Olefirowicz E.M., Wetzel J.R., Alexander M.D., Weaver J.D., Haycock D.A., Luttinger D.A., Casiano F.M., Chippari S.M., Kuster J.E., Stevenson J.I., Ward S.J. Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. J. Med. Chem. 38:1995;3094-3105.
46. 2+-dependent release from rat brain of cannabinoid receptor binding activity. J. Neurochem. 58:1992;780-782.
47. Evans D.M., Lake J.T., Johnson M.R., Howlett A.C. Endogenous cannabinoid receptor binding activity released from rat brain slices by depolarization. J. Pharmacol. Exp. Ther. 268:1994;1271-1277.
48. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA. 92:1995;3376-3380.
49. 1 cannabinoid receptor. Soc. Neurosci. Abstr. 21:1995;1144.
50. Fan F., Tao Q., Abood M., Martin B.R. Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice. Brain Res. 706:1996;13-20.
51. 3 receptors in rat nodose ganglion neurons. J. Neurophysiol. 73:1995;907-910.
52. Feigenbaum J.J., Bergmann F., Richmond S.A., Mechoulam R., Nadler V., Kloog Y., Sokolovsky M. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc. Natl. Acad. Sci. USA. 86:1989;9584-9587.
53. Felder C.C., Veluz J.S., Williams H.L., Briley E.M., Matsuda L.A. Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol. Pharmacol. 42:1992;838-845.
54. Felder C.C., Briley E.M., Axelrod J., Simpson J.T., Mackie K., Devane W.A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA. 90:1993;7656-7660.
55. 2 receptors. Mol. Pharmacol. 48:1995;443-450.
56. Felder C.C., Nielsen A., Briley E.M., Palkovits M., Priller J., Axelrod J., Nguyen D.N., Richardson J.M., Riggin R.M., Koppel G.A., Paul S.M., Becker G.W. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 393:1996;231-235.
57. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 231:1993;313-314.
58. 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 272:1995;699-707.
59. Galiègue S., Mary S., Marchand J., Dussossoy D., Carrière D., Carayon P., Bouaboula M., Shire D., Le Fur G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232:1995;54-61.
60. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86:1964;1646-1647.
61. Gareau Y., Dufresne C., Gallant M., Rochette C., Sawyer N., Slipetz D.M., Tremblay N., Weech P.K., Metters K.M., Labelle M. Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors. Bioorg. Med. Chem. Lett. 6:1996;189-194.
62. Gérard C., Mollereau C., Vassart G., Parmentier M. Nucleotide sequence of a human cannabinoid receptor cDNA. Nucl. Acids Res. 18:1991;7142.
63. Gérard C.M., Mollereau C., Vassart G., Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J. 279:1991;129-134.
64. Gifford A.N., Ashby C.R. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J. Pharmacol. Exp. Ther. 277:1996;1431-1436.
65. Glass M., Dragunow M. Induction of the Krox 24 transcription factor in striosomes by a cannabinoid agonist. Neuroreport. 6:1995;241-244.
66. Glass M., Faull R.L.M., Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience. 56:1993;523-527.
67. 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 262:1992;479-486.
68. Hampson A.J., Hill W.A.G., Zan-Phillips M., Makriyannis A., Leung E., Eglen R.M., Bornheim L.M. Anandamide hydroxylation by brain lipoxygenase: metabolite structures and potencies at the cannabinoid receptor. Biochim. Biophys. Acta. 1259:1995;173-179.
69. Hanuš L., Gopher A., Almog S., Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 36:1993;3032-3034.
70. Henry D.J., Chavkin C. Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci. Lett. 186:1995;91-94.
71. Herkenham M. Localization of cannabinoid receptors in brain and periphery. Pertwee R.G. Cannabinoid Receptors. 1995;145-166 Academic Press, London.
72. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA. 87:1990;1932-1936.
73. Herkenham M., Groen B.G.S., Lynn A.B., de Costa B.R., Richfield E.K. Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum. Brain Res. 552:1991a;301-310.
74. Herkenham M., Lynn A.B., de Costa B.R., Richfield E.K. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 547:1991b;267-274.
75. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:1991c;563-583.
76. Hillard C.J., Edgemond W.S., Campbell W.B. Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide. J. Neurochem. 64:1995a;677-683.
77. Hillard C.J., Wilkison D.M., Edgemond W.S., Campbell W.B. Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim. Biophys. Acta. 1257:1995b;249-256.
78. Hirst R.A., Lambert D.G. Do SH-SY5Y human neuroblastoma cells express cannabinoid receptors? Biochem. Soc. Trans. 23:1995;418S.
79. Ho B.Y., Zhao J. Determination of the cannabinoid receptors in mouse x rat hybridoma NG108-15 cells and rat GH4C1 cells. Neurosci. Lett. 212:1996;123-126.
80. Hoehe M.R., Caenazzo L., Martinez M.M., Hsieh W.-T., Modi W.S., Gershon E.S., Bonner T.I. Genetic and physical mapping of the human cannabinoid receptor gene to chromosome-6q14-q15. New Biol. 3:1991;880-885.
81. Hollister L.E. Health aspects of cannabis. Pharmacol. Rev. 38:1986;1-20.
82. Holsapple M.P., Karras J.G., Ledbetter J.A., Schieven G.L., Burchiel S.W., Davila D.R., Schatz A.R., Kaminski N.E. Molecular mechanisms of toxicant-induced immunosuppression: role of second messengers. Annu. Rev. Pharmacol. Toxicol. 36:1996;131-159.
83. Hong S.J., Roan Y.F., Chang C.C. Inhibition of neuromuscular transmission in the myenteric plexus of guinea-pig ileum by ω-conotoxins GVIA, MVIIA, MVIIC and SVIB. Br. J. Pharmacol. 118:1996;797-803.
84. Houston D.B., Howlett A.C. Solubilization of the cannabinoid receptor from rat brain and its functional interaction with guanine nucleotide-binding proteins. Mol. Pharmacol. 43:1993;17-22.
85. Howlett A. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci. 35:1984;1803-1810.
86. Howlett A.C. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol. Pharmacol. 27:1985;429-436.
87. Howlett A.C. Cannabinoid inhibition of adenylate cyclase: relative activity of constituents and metabolites of marihuana. Neuropharmacology. 26:1987;507-512.
88. Howlett A.C. Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 33:1995a;607-634.
89. Howlett A.C. Cannabinoid compounds and signal transduction mechanisms. Pertwee R.G. Cannabinoid Receptors. 1995b;167-204 Academic Press, London.
90. Howlett A.C., Fleming R.M. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol. Pharmacol. 26:1984;532-538.
91. 1 in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol. 29:1986;307-313.
92. Howlett A.C., Johnson M.R., Melvin L.S., Milne G.M. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol. Pharmacol. 33:1988;297-302.
93. 8-tetrahydro-cannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology. 29:1990;161-165.
94. Howlett A.C., Evans D.M., Houston D.B. The cannabinoid receptor. Murphy L., Bartke A. Marijuana/Cannabinoids. 1992;35-72 CRC Press, Inc. Boca Raton. Neurobiology and Neurophysiology.
95. Huffman J.W., Lainton J.A.H. Recent developments in the medicinal chemistry of cannabinoids. Curr. Med. Chem. 3:1996;101-116.
96. Huffman J.W., Dai D., Martin B.R., Compton D.R. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg. Med. Chem. Lett. 4:1994;563-566.
97. 2 receptor. J. Med. Chem. 39:1996;3875-3877.
98. 1 receptors on peripheral sympathetic nerves. Br. J. Pharmacol. 118:1996;2023-2028.
99. Jansen E.M., Haycock D.A., Ward S.J., Seybold V.S. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Res. 575:1992;93-102.
100. Järbe T.U.C., Hiltunen A.J., Mathis D.A., Hanuš L., Breuer A., Mechoulam R. Discriminative stimulus effects and receptors binding of enantiomeric pairs of cannabinoids in rats and pigeons; a comparison. J. Pharmacol. Exp. Ther. 264:1993;561-569.
101. Johnson M.R., Melvin L.S. The discovery of non-classical cannabinoid analgetics. Mechoulam R. Cannabinoids as Therapeutic Agents. 1986;121-145 CRC Press, Boca Raton.
102. Kaminski N.E., Abood M.E., Kessler F.K., Martin B.R., Schatz A.R. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol. Pharmacol. 42:1992;736-742.
103. Kaminski N.E., Koh W.S., Yang K.H., Lee M., Kessler F.K. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochem. Pharmacol. 48:1994;1899-1908.
104. Kenakin T. 2nd edn. Pharmacologic Analysis of Drug-Receptor Interaction. 1993;Raven Press, New York.
105. Koutek B., Prestwich G.D., Howlett A.C., Chin S.A., Salehani D., Akhavan N., Deutsch D.G. Inhibitors of arachidonoyl ethanolamide hydrolysis. J. Biol. Chem. 269:1994;22937-22940.
106. Kuster J.E., Stevenson J.I., Ward S.J., D'Ambra T.E., Haycock D.A. Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J. Pharmacol. Exp. Ther. 264:1993;1352-1363.
107. Lainton J.A.H., Huffman J.W., Martin B.R., Compton D.R. 1-Alkyl-3-(1-naphthoyl)pyrroles: a new class of cannabinoid. Tetrahedron Lett. 36:1995;1401-1404.
108. Lee M., Yang K.H., Kaminski N.E. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J. Pharmacol. Exp. Ther. 275:1995;529-536.
109. Lu R.S., Hubbard J.R., Martin B.R., Kalimi M.Y. Roles of sulfhydryl and disulfide groups in the binding of CP-55,940 to rat brain cannabinoid receptor. Mol. Cell. Biochem. 121:1993;119-126.
110. Lynn A.B., Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat-implications for receptor-mediated immune modulation by cannabinoids. J. Pharmacol. Exp. Ther. 268:1994;1612-1623.
111. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA. 89:1992;3825-3829.
112. Mackie K., Devane W.A., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44:1993;498-503.
113. Mackie K., Lai Y., Westenbroek R., Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15:1995;6552-6561.
114. Mailleux P., Vanderhaeghen J.-J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 48:1992a;655-668.
115. Mailleux P., Vanderhaeghen J.-J. Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neurosci. Lett. 148:1992b;173-176.
116. Mailleux P., Verslijpe M., Vanderhaeghen J.-J. Initial observations on the distribution of cannabinoid receptor binding sites in the human adult basal ganglia using autoradiography. Neurosci. Lett. 139:1992;7-9.
117. Makriyannis A. The role of cell membranes in cannabinoid activity. Pertwee R.G. Cannabinoid Receptors. 1995;87-115 Academic Press, London.
118. 9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus. Eur. J. Pharmacol. 308:1996;161-164.
119. 1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology. 124:1996;315-322.
120. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johnson M.R., Melvin L.S., Mechoulam R., Ward S.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40:1991;471-478.
121. Martin B.R., Compton D.R., Prescott W.R., Barrett R.L., Razdan R.K. Pharmacological evaluation of dimethylheptyl analogs of delta-9-THC: reassessment of the putative three-point cannabinoid-receptor interaction. Drug Alcohol Depend. 37:1995a;231-240.
122. Martin B.R., Thomas B.F., Razdan R.K. Structural requirements for cannabinoid receptor probes. Pertwee R.G. Cannabinoid Receptors. 1995b;35-85 Academic Press, London.
123. Matsuda L.A., Bonner T.I. Molecular biology of the cannabinoid receptor. Pertwee R.G. Cannabinoid Receptors. 1995;117-143 Academic Press, London.
124. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
125. McLaughlin C.R., Martin B.R., Compton D.R., Abood M.E. Cannabinoid receptors in developing rats: detection of mRNA and receptor binding. Drug Alcohol Depend. 36:1994;27-31.
126. Mechoulam R., Fride E. The unpaved road to the endogenous brain cannabinoid ligands, the anandamides. Pertwee R.G. Cannabinoid Receptors. 1995;233-258 Academic Press, London.
127. Mechoulam R., Devane W.A., Glaser R. Cannabinoid geometry and biological activity. Murphy L., Bartke A. Marijuana/Cannabinoids. Neurobiology and Neurophysiology. 1992;1-33 CRC Press, Inc. Boca Raton.
128. Mechoulam R., Ben-Shabat S., Hanuš L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., Pertwee R.G., Griffin G., Bayewitch M., Barg J., Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:1995;83-90.
129. Melvin L.S., Milne G.M., Johnson M.R., Subramaniam B., Wilken G.H., Howlett A.C. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol. Pharmacol. 44:1993;1008-1015.
130. Milligan G., Bond R.A., Lee M. Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol. Sci. 16:1995;10-13.
131. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
132. Nah S.-Y., Saya D., Vogel Z. Cannabinoids inhibit agonist-stimulated formation of inositol phosphates in rat hippocampal cultures. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 246:1993;19-24.
133. 2+ concentration in rats. Neurosci. Lett. 140:1992;55-58.
134. Onaivi E.S., Chakrabarti A., Chaudhuri G. Cannabinoid receptor genes. Prog. Neurobiol. 48:1996a;275-305.
135. 1) receptor gene expression in mice. Behav. Brain Res. 72:1996b;115-125.
136. Oviedo A., Glowa J., Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res. 616:1993;293-302.
137. Pacheco M., Childers S.R., Arnold R., Casiano F., Ward S.J. Aminoalkylindoles: actions on specific G-protein-linked receptors. J. Pharmacol. Exp. Ther. 257:1991;170-183.
138. Pacheco M.A., Ward S.J., Childers S.R. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Res. 603:1993;102-110.
139. Pacheco M.A., Ward S.J., Childers S.R. Differential requirements of sodium for coupling of cannabinoid receptors to adenylyl cyclase in rat brain membranes. J. Neurochem. 62:1994;1773-1782.
140. 2+ channels in a neuronal expression system. Mol. Pharmacol. 49:1996;707-714.
141. Paria B.C., Das S.K., Dey S.K. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling. Proc. Natl. Acad. Sci. USA. 92:1995;9460-9464.
142. Paterson S.J., Pertwee R.G. Characterization of the cannabinoid binding site in the guinea-pig. Br. J. Pharmacol. 109:1993;82P. (Proc. Suppl.).
143. 1 antagonist, SR 141716A. Behav. Pharmacol. 7:1996;65-71.
144. Pertwee R.G. The central neuropharmacology of psychotropic cannabinoids. Pharmacol. Ther. 36:1988;189-261.
145. Pertwee R.G. Tolerance to and dependence on psychotropic cannabinoids. Pratt J.A. The Biological Bases of Drug Tolerance and Dependence. 1991;231-263 Academic Press, London.
146. Pertwee R. The evidence for the existence of cannabinoid receptors. Gen. Pharmacol. 24:1993;811-824.
147. Pertwee R.G. Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors: an overview. Pertwee R.G. Cannabinoid Receptors. 1995;1-34 Academic Press, London.
148. 1 receptors in mouse urinary bladder. Br. J. Pharmacol. 118:1996;2053-2058.
149. Pertwee R.G., Griffin G. A preliminary investigation of the mechanisms underlying cannabinoid tolerance in the mouse vas deferens. Eur. J. Pharmacol. 272:1995;67-72.
150. Pertwee R.G., Stevenson L.A., Elrick D.B., Mechoulam R., Corbett A.D. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br. J. Pharmacol. 105:1992;980-984.
151. Pertwee R.G., Stevenson L.A., Fernando S.R., Corbett A.D. In vitro effects of the cannabinoid, CP 55,940, and of its (+)-enantiomer, CP 56,667. Harris L. Problems of Drug Dependence, 1992: Proceeding of the 54th Annual Scientific Meeting of the College on Problems of Drug Dependence, Inc.: National Institute on Drug Abuse Research Monograph Series. 1993;374 National Institute on Drug Abuse, Rockville.
152. Pertwee R., Griffin G., Hanuš L., Mechoulam R. Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. Eur. J. Pharmacol. 259:1994;115-120.
153. Pertwee R.G., Fernando S.R., Griffin G., Abadji V., Makriyannis A. Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur. J. Pharmacol. 272:1995a;73-78.
154. Pertwee R., Griffin G., Fernando S., Li X., Hill A., Makriyannis A. AM630, a competitive cannabinoid receptor antagonist. Life Sci. 56:1995b;1949-1955.
155. Pertwee R.G., Griffin G., Lainton J.A.H., Huffman J.W. Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens. Eur. J. Pharmacol. 284:1995c;241-247.
156. 8-tetrahydro-cannabinol in two isolated tissue preparations. Eur. J. Pharmacol. 315:1996a;195-201.
157. 1 receptors in guinea-pig small intestine. Br. J. Pharmacol. 118:1996b;2199-2205.
158. 1 receptors in mouse vas deferens. Eur. J. Pharmacol. 296:1996c;169-172.
159. 3H]SR141716A. Neuroreport. 7:1996;789-792.
160. Pinto J.C., Potié F., Rice K.C., Boring D., Johnson M.R., Evans D.M., Wilken G.H., Cantrell C.H., Howlett A.C. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol. Pharmacol. 46:1994;516-522.
161. 2) cannabinoid receptors. Mol. Pharmacol. 48:1995;288-292.
162. Pugh G., Welch S.P., Bass P.P. Modulation of free intracellular calcium and cAMP by morphine and cannabinoids, alone and in combination in mouse brain and spinal cord synaptosomes. Pharmacol. Biochem. Behav. 49:1994;1093-1100.
163. Razdan R.K. Structure-activity relationships in cannabinoids. Pharmacol. Revs. 38:1986;75-149.
164. 9-tetrahydrocannabinol-induced analgesia in mice. Eur. J. Pharmacol. 301:1996;75-81.
165. 9-Tetrahydrocannabinol inhibits arachidonic acid acylation of phospholipids and triacylglycerols in guinea pig cerebral cortex slices. Mol. Pharmacol. 40:1991;547-555.
166. Richfield E.K., Herkenham M. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. 36:1994;577-584.
167. Rinaldi-Carmona M., Barth F., Héaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Néliat G., Caput D., Ferrara P., Soubrié P., Brelière J.-C., Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
168. 1) cannabinoid receptor antagonist, in rodent brain. Life Sci. 58:1996;1239-1247.
169. Rodríguez de Fonseca F., Ramos J.A., Bonnin A., Fernández-Ruiz J.J. Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport. 4:1993;135-138.
170. 9-tetrahydrocannabinol treatment. Pharmacol. Biochem. Behav. 47:1994;33-40.
171. 9-tetrahydrocannabinol. Pharmacol. Biochem. Behav. 51:1995;731-737.
172. Rowley J.T., Rowley P.T. Tetrahydrocannabinol inhibits adenyl cyclase in human leukemia cells. Life Sci. 46:1990;217-222.
173. Rubino T., Massi P., Patrini G., Venier I., Giagnoni G., Parolaro D. Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study. Neuroreport. 5:1994;2493-2496.
174. 1 cannabinoid receptor antagonist SR141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci. 58:1996;PL103-PL110.
175. 9-tetrahydrocannabinol in mouse spleen cells: a potential mechanism for cannabinoid-mediated immunosuppression. Life Sci. 51:1992;25-30.
176. Selley D.E., Breivogel C.S., Childers S.R. Modification of G protein-coupled functions by low-pH pretreatment of membranes from NG108-15 cells: increase in opioid agonist efficacy by decreased inactivation of G proteins. Mol. Pharmacol. 44:1993;731-741.
177. Selley D.E., Stark S., Sim L.J., Childers S.R. Cannabinoid receptor stimulation of guanosine-5′-O-(3-[35S]thio) triphosphate binding in rat brain membranes. Life Sci. 59:1996;659-668.
178. Shire D., Carillon C., Kaghad M., Calandra B., Rinaldi-Carmona M., Le Fur G., Caput D., Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270:1995;3726-3731.
179. 1 antagonist SR 141716A. J. Biol. Chem. 271:1996a;6941-6946.
180. 2 peripheral cannabinoid receptor. Biochim. Biophys. Acta. 1307:1996b;132-136.
181. 9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboximide hydrochloride]. Biochem. Pharmacol. 51:1996;669-676.
182. Shohami E., Novikov M., Bass R. Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the rat. Brain Res. 674:1995;55-62.
183. Showalter V.M., Compton D.R., Martin B.R., Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278:1996;989-999.
184. 35S]thiol-triphosphate binding. Proc. Natl. Acad. Sci. USA. 92:1995;7242-7246.
185. Sim L.J., Selley D.E., Xiao R., Childers S.R. Differences in G-protein activation by μ- and δ-opioid, and cannabinoid receptors in rat striatum. Eur. J. Pharmacol. 307:1996;97-105.
186. Slipetz D.M., O'Neill G.P., Favreau L., Dufresne C., Gallant M., Gareau Y., Guay D., Labelle M., Metters K.M. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol. Pharmacol. 48:1995;352-361.
187. Song Z.-H., Bonner T.I. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN 55212-2. Mol. Pharmacol. 49:1996;891-896.
188. Stubbs L., Chittenden L., Chakrabarti A., Onaivi E. The gene encoding the central cannabinoid receptor is located in proximal mouse Chromosome 4. Mamm. Genome. 7:1996;165-166.
189. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoyl-glycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215:1995;89-97.
190. 1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology. 126:1996;165-172.
191. 9-THC-DMH. J. Pharmacol. Exp. Ther. 263:1992;1383-1390.
192. Thomas B.F., Adams I.B., Mascarella S.W., Martin B.R., Razdan R.K. Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore. J. Med. Chem. 39:1996;471-479.
193. Turkanis S.A., Karler R., Partlow L.M. Differential effects of delta-9-tetrahydrocannabinol and its 11-hydroxy metabolite on sodium current in neuroblastoma cells. Brain Res. 560:1991a;245-250.
194. Turkanis S.A., Partlow L.M., Karler R. Delta-9-tetrahydrocannabinol depresses inward sodium current in mouse neuroblastoma cells. Neuropharmacology. 30:1991b;73-77.
195. Vogel Z., Barg J., Levy R., Saya D., Heldman E., Mechoulam R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem. 61:1993;352-355.
196. Wartmann M., Campbell D., Subramanian A., Burstein S.H., Davis R.J. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. FEBS Lett. 359:1995;133-136.
197. Waterman S.A. Multiple subtypes of voltage-gated calcium channel mediate transmitter release from parasympathetic neurons in the mouse bladder. J. Neurosci. 16:1996;4155-4161.
198. Westlake T.M., Howlett A.C., Bonner T.I., Matsuda L.A., Herkenham M. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience. 63:1994;637-652.
199. Wiley J., Balster R., Martin B. Discriminative stimulus effects of anandamide in rats. Eur. J. Pharmacol. 276:1995a;49-54.
200. Wiley J.L., Barrett R.L., Lowe J., Balster R.L., Martin B.R. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology. 34:1995b;669-676.
201. 9-tetrahydrocannabinol in rhesus monkeys. Drug Alcohol Depend. 40:1995c;81-86.
202. 9-tetrahydrocannabinol in rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 275:1995d;1-6.
203. Wise M.L., Soderstrom K., Murray T.F., Gerwick W.H. Synthesis and cannabinoid receptor binding activity of conjugated triene anandamide, a novel eicosanoid. Experientia. 52:1996;88-92.
204. Wright C.E., Angus J.A. Effects of N-, P- and Q-type neuronal calcium channel antagonists on mammalian peripheral neurotransmission. Br. J. Pharmacol. 119:1996;49-56.
205. Xie X.-Q., Eissenstat M., Makriyannis A. Common cannabimimetic pharmacophoric requirements between aminoalkyl indoles and classical cannabinoids. Life Sci. 56:1995;1963-1970.
206. Xie X.-Q., Melvin L.S., Makriyannis A. The conformational properties of the highly selective cannabinoid receptor ligand CP-55,940. J. Biol. Chem. 271:1996;10640-10647.
207. 1-tetrahydrocannabinol. Science. 177:1972;442-444.